Circulating glycosaminoglycan anticoagulants associated with suramin treatment.
A complex coagulopathy appeared in three women receiving suramin as treatment for metastatic adrenocortical carcinoma. Although hepatocellular dysfunction accounted for some of the abnormality, a unique feature of the coagulopathy was the presence of an inhibitor of the thrombin clotting time. The potency of this circulating anticoagulant increased markedly during exacerbations of hepatic injury. The anticoagulant was removed from plasma samples from two of the patients by passage over a column of diethylaminoethyl (DEAE)-Sephacel. It eluted from the DEAE at salt concentrations that removed "high-charge" glycosaminoglycans. Elimination of the purified anticoagulant activity in vitro required a combination of heparitinase and chondroitinase ABC, suggesting that the activity was mediated by both heparan sulfate and dermatan sulfate. Suramin is hypothesized to inhibit enzymes that normally degrade glycosaminoglycans, resulting in accumulation of these substances, which are released from the liver into the circulation during periods of hepatic injury.
Horne
M K
MK
Clinical Pathology Department, National Cancer Institute, Bethesda, MD 20892.
Stein
C A
CA
LaRocca
R V
RV
Myers
C E
CE
D000328:Adult; D000925:Anticoagulants / Q000097:blood*; D001777:Blood Coagulation / Q000187:drug effects; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D002848:Chromatography, DEAE-Cellulose; D004586:Electrophoresis; D005260:Female; D006025:Glycosaminoglycans / Q000097:blood* / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008107:Liver Diseases / Q000097:blood; D013498:Suramin / Q000009:adverse effects* / Q000494:pharmacology
D000925:Anticoagulants; D006025:Glycosaminoglycans; D013498:Suramin